Versigent (NYSE:VGNT) Given New $56.00 Price Target at Wells Fargo & Company

Versigent (NYSE:VGNTGet Free Report) had its target price boosted by Wells Fargo & Company from $48.00 to $56.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 22.86% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. BNP Paribas Exane started coverage on Versigent in a report on Tuesday, April 28th. They set an “outperform” rating and a $41.00 price target on the stock. Zacks Research raised Versigent from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 2nd. Wolfe Research began coverage on shares of Versigent in a research note on Thursday, April 30th. They set an “outperform” rating and a $53.00 target price on the stock. Oppenheimer set a $50.00 price objective on shares of Versigent in a research report on Tuesday, July 21st. Finally, Argus set a $50.00 target price on shares of Versigent in a research note on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Versigent presently has an average rating of “Buy” and a consensus target price of $51.25.

View Our Latest Report on Versigent

Versigent Stock Down 0.5%

VGNT stock traded down $0.22 during midday trading on Wednesday, hitting $45.58. The company’s stock had a trading volume of 179,073 shares, compared to its average volume of 2,068,530. The firm has a 50-day moving average of $43.38. Versigent has a 52-week low of $26.34 and a 52-week high of $50.88.

Versigent (NYSE:VGNTGet Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.34. The company had revenue of $2.44 billion for the quarter, compared to analysts’ expectations of $2.29 billion.

Featured Articles

Analyst Recommendations for Versigent (NYSE:VGNT)

Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.